Active Biotech Q3 2023: Rights Issue Paves the Way for Phase II in Myelofibrosis - Redeye
Bildkälla: Stockfoto

Active Biotech Q3 2023: Rights Issue Paves the Way for Phase II in Myelofibrosis - Redeye

Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced.

Börsvärldens nyhetsbrev